MISSISSAUGA, Ontario, Sept. 15, 2014 – Covalon Technologies Ltd. (TSXV: COV), an advanced medical technologies company, returns to MEDICA for the third consecutive year to showcase its portfolio of innovative and transformative products and product concepts in the area of Wound Care and Infection Control.
- ColActive® Plus – Wound Balancing Matrix, the market’s only advanced wound dressing which targets elevated protease activity in two ways, and contains both CMC and alginate for optimal wound moisture balance
- SilverCoat™ Antimicrobial Foley Catheter, which delivers an unsurpassed level of protection against urinary tract infections
- MediClear™ Pre-Operative Skin Protective Film, the first antimicrobial adhesive film product designed to deliver bactericidal activity that overcomes both patient compliance and skin issues associated with traditional skin prep cloths
- ColActive® THP – Topical Hydromatrix Pad and its next generation ColActive® THP Hemostat which, pending FDA clearance, will revolutionize the way clinicians gel clot formation following a procedure.
Covalon will showcase these advanced wound care and infection control technologies at MEDICA 2014, the world’s largest annual medical trade fair, from November 12 to 15 in Düsseldorf, Germany.
"We are very excited about what these products bring to advanced wound care and infection control,” says John Hands, Senior Director of Global Marketing. “Through our patented, platform technologies, our scientists have been able to offer never before seen products and product concepts.
“Our focus is to provide technology that addresses the needs of our customers, whether they are a large OEM or a private wound clinic. I encourage those who have business relating to wound care or infection control to visit us at MEDICA,” says Hands.
To learn more about Covalon’s products and services, please come see us during MEDICA at the Ontario/Canada Pavilion, Hall 16, Booth G42 and visit the Covalon website www.covalon.com beforehand. You may also look us up under “Companies & Products" on the medica-tradefair.com portal
Note: Products described above are not commercially available in the EU.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in speciality areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com. Follow on Twitter @covalon.
CEO, Covalon Technologies Ltd.
T: (905) 568-8400 x 233
F: (905) 568-5200
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.